Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle‐controlled exploratory trial. Issue 8 (24th December 2015)

• Record Type: Journal Article
• Authors: Nemoto, Osamu; Hayashi, Nobukazu; Kitahara, Yasumi; Furue, Masutaka; Hojo, Seiichiro; Nomoto, Maiko; Shima, Satoshi
• Other Names: Asanuma Hiroyuki investigator.; Saga Kenji investigator.; Takahashi Yoshimasa investigator.; Morikawa Reiko investigator.; Hagiwara Kazuya investigator.; Sugawara Hiroshi investigator.; Takata Hideyasu investigator.; Etoh Takafumi investigator.
• Is Part Of: Journal of dermatology. Volume 43:Issue 8(2016)
• Page Start: 881
• Page End: 887
• Publication Date: 2015-12-24
• Subjects: atopic dermatitis -- children -- E6005 -- phosphodiesterase 4 inhibitor -- topical drug; Dermatology -- Periodicals; Dermatology -- Japan -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1111/1346-8138.13231
• Languages: English
• ISSNs: 0385-2407

Abstract

Abstract: This exploratory study was designed to evaluate the safety and efficacy profile of the topical phosphodiesterase 4 inhibitor E6005 in Japanese children with mild‐to‐moderate atopic dermatitis. The present randomized, multicenter study included 62 patients who were treated with 0.05% E6005, 0.2% E6005 or vehicle ointment twice daily for 2 weeks. Safety and pharmacokinetics were assessed with a focus on the occurrence of adverse events and the whole blood concentrations of E6005 and its metabolite. Exploratory efficacy evaluations included assessments of lesion severity and pruritus score. The 2‐week application of topical E6005 was safe and well tolerated with no cutaneous adverse events. The whole blood concentration of E6005 was quantified in only one subject receiving 0.2% E6005 treatment, while its major metabolite was undetectable. The 0.2% E6005 group showed a greater decrease in the severity score than the vehicle group (−45.94% vs −32.26%), although this difference was not statistically significant. Similarly, the treatment success rate according to the investigator's global assessment of the total application sites was higher in the 0.2% E6005 group than in the vehicle group (34.4% vs 20.0%). Moreover, the 0.2% E6005 group showed a greater decrease in the pruritus score than the vehicle group (−37.5% vs −6.7%) in a predefined subpopulation. The efficacy of 0.05% E6005 treatment was comparable to that of vehicle treatment. These results suggest that topical 0.2% E6005 treatment is safe and effective in children with atopic dermatitis, although further large confirmatory clinical trials are warranted.